Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 4:13:839094.
doi: 10.3389/fimmu.2022.839094. eCollection 2022.

Coexistence of Anti-p200 Pemphigoid and Psoriasis: A Systematic Review

Affiliations

Coexistence of Anti-p200 Pemphigoid and Psoriasis: A Systematic Review

Ying-Han Xie et al. Front Immunol. .

Abstract

Background: A close association between psoriasis and anti-p200 pemphigoid has been demonstrated by numerous studies. However, the clinical characteristics of patients suffering from these two entities have not yet been well-elucidated.

Objective: This study aimed to review the case reports and case series, summarizing clinical features and therapeutic strategies in patients suffering from anti-p200 pemphigoid and psoriasis.

Methods: A systematic review was conducted by searching PubMed, EMBASE, and Web of Science databases for studies published in English involving patients with psoriasis and anti-p200 pemphigoid on 6 September 2021. All case reports and case series reporting patients diagnosed with anti-p200 pemphigoid and psoriasis were included in this systematic review.

Results: A total of 21 eligible studies comprising 26 anti-p200 pemphigoid patients with preceding psoriasis were included in the qualitative synthesis. The average age at blisters eruption was 62.5 years, and the mean duration between the two entities was 15.6 years. Twenty-four percent of patients developed bullous lesions during UV therapy. Clinical manifestation of bullae and/or vesicles was recorded in all patients, and the trunk (94.7%) was most frequently involved, with only 15.8% reporting mucosal involvement. Epitope spreading was detected by immunoblotting in 33.3% of patients. All the patients reached completed remission during the course of disease, with 36.8% experiencing at least one relapse. Monotherapy of prednisolone was the leading therapeutic approach (n=6, 31.6%) required for disease control, but 5 (83.3%) of them suffered from blister recurrence after tapering or ceasing corticosteroid.

Conclusion: Most of the clinical aspects of patients with anti-p200 pemphigoid and psoriasis were similar to what was demonstrated in previous articles on anti-p200 pemphigoid. Nevertheless, compared with other anti-p200 pemphigoid cases without psoriasis, a clinical manifestation pattern with more frequent involvement of the trunk and less mucosal involvement was illustrated in those with psoriasis. Generally, monotherapy is sufficient for a complete remission for such patients. However, one or more relapses have been recorded in a considerable portion of patients, especially those prescribed with prednisolone. It reminded us to be more cautious during a tapering of medication.

Keywords: anti-laminin γ1 pemphigoid; anti-p200 pemphigoid; epitope spreading; psoriasis; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart for the process of article screening and selection on three databases.
Figure 2
Figure 2
Histology in patients with anti-p200 pemphigoid and psoriasis. The numbers of patients with different inflammatory cell infiltration were shown. The overlaps of circles indicated that patients were detected with infiltration patterns of mixed inflammatory cells.

Similar articles

Cited by

References

    1. Chen KR, Shimizu S, Miyakawa S, Ishiko A, Shimizu H, Hashimoto T. Coexistence of Psoriasis and an Unusual Igg-Mediated Subepidermal Bullous Dermatosis: Identification of a Novel 200-Kda Lower Lamina Lucida Target Antigen. Br J Dermatol (1996) 134(2):340–6. doi: 10.1111/j.1365-2133.1996.tb07625.x - DOI - PubMed
    1. Zillikens D, Kawahara Y, Ishiko A, Shimizu H, Mayer J, Rank CV, et al. . A Novel Subepidermal Blistering Disease With Autoantibodies to a 200-Kda Antigen of the Basement Membrane Zone (Vol 106 1996). J Invest Dermatol (1996) 106(6):1332–8:pg 465. doi: 10.1111/1523-1747.ep12349283 - DOI - PubMed
    1. Dainichi T, Koga H, Tsuji T, Ishii N, Ohyama B, Ueda A, et al. . From Anti-P200 Pemphigoid to Anti-Laminin Γ1 Pemphigoid. J Dermatol (2010) 37(3):231–8. doi: 10.1111/j.1346-8138.2009.00793.x - DOI - PubMed
    1. Dainichi T, Kabashima K. Interaction of Psoriasis and Bullous Diseases. Front Med (2018) 5:222. doi: 10.3389/fmed.2018.00222 - DOI - PMC - PubMed
    1. Lau I, Goletz S, Holtsche MM, Zillikens D, Fechner K, Schmidt E. Anti-P200 Pemphigoid Is the Most Common Pemphigoid Disease With Serum Antibodies Against the Dermal Side by Indirect Immunofluorescence Microscopy on Human Salt-Split Skin. J Am Acad Dermatol (2019) 81(5):1195–7. doi: 10.1016/j.jaad.2019.03.077 - DOI - PubMed

Publication types